Clinical Trial Title
A phase III, multicentre, randomised, double-blind, controlled study to investigate the efficacy, safety, and tolerability of two initial administrations of COMP360 in participants with treatment-resistant depressionNational Clinical Trial Number:
NCT05711940Contact Information
Clinical Trial Protocol Description:
A study to assess the safety and efficacy of COMP360 (COMPASS Pathfinder Limited’s proprietary synthetic psilocybin formulation) delivered with psychological support (25 mg and 10 mg versus 1 mg) in participants with treatment-resistant depression.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Are 18 years of age or older.
- Have been diagnosed with major depression.
- Have failed 2, 3 or 4 treatments during your current episode of depression (supported by medical records or other documentation from your healthcare provider).
You will be excluded from the study if any of the following criteria apply to you:
- Are pregnant or planning a pregnancy.
- Have a history of certain other psychiatric disorders or medical conditions.
- Have a seizure disorder.
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.
Study Details
Clinical Trial Investigator
John Zajecka, MD
Contact Information
Linda Skaggs
Clinical Trial Location
RUSH University Medical Center